Trials / No Longer Available
No Longer AvailableNCT03424473
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Seagen Inc. · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information (medinfo@seagen.com).
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tucatinib |
Timeline
- First posted
- 2018-02-07
- Last updated
- 2020-02-25
Source: ClinicalTrials.gov record NCT03424473. Inclusion in this directory is not an endorsement.